KALA BIO, INC. Proceeds from Long-Term Debt Issued
KALA BIO, INC. (KALA) reported Proceeds from Long-Term Debt Issued of $77.78 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2023-03-03
- KALA BIO, INC. proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $0.00.
- KALA BIO, INC. proceeds from issuance of long-term debt for the quarter ending 2021-09-30 was $0.00.
- KALA BIO, INC. proceeds from issuance of long-term debt for the quarter ending 2018-12-31 was $69.20M.
- KALA BIO, INC. proceeds from issuance of long-term debt for the quarter ending 2018-09-30 was $0.00.
- KALA BIO, INC. proceeds from issuance of long-term debt for fiscal 2021 was $77.78M.
- KALA BIO, INC. proceeds from issuance of long-term debt for fiscal 2018 was $71.93M, a 619.27% increase from fiscal 2017.
- KALA BIO, INC. proceeds from issuance of long-term debt for fiscal 2017 was $10.00M, a 650.19% increase from fiscal 2016.
- KALA BIO, INC. proceeds from issuance of long-term debt for fiscal 2016 was $1.33M, a 73.34% decline from fiscal 2015.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $0.00 derived: sum of 2 quarters · filed 2023-03-03 | $77.78M 10-K · filed 2023-03-03 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $77.78M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $77.78M 10-Q · filed 2022-08-11 | |||
| 2018-12-31 | $69.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $69.20M derived: sum of 2 quarters · filed 2020-02-12 | $69.20M derived: sum of 3 quarters · filed 2020-02-12 | $71.93M 10-K · filed 2020-02-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $2.73M 10-Q · filed 2018-11-08 | $2.73M derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $2.73M 10-Q · filed 2018-08-09 | $2.73M derived: sum of 3 quarters · filed 2018-08-09 | |
| 2018-03-31 | $2.73M 10-Q · filed 2018-05-10 | $2.73M derived: sum of 2 quarters · filed 2018-05-10 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $10.00M 10-K · filed 2018-04-02 | ||
| 2017-09-30 | $10.00M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | $1.33M 10-K · filed 2018-04-02 | |||
| 2015-12-31 | $5.00M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |